**Malignant Hematology Clinical Trials**

- **UCI-13-02**: Assessing Fitness and Physical Activity in Acute Lymphoblastic Leukemia (ALL) Patients in Remission (Aizik)
- **UCI-14-03**: Role of inflammation in the pathogenesis of myeloproliferative neoplasm (Fleischman)
- **UCI-16-01**: Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)
- **UCI 15-65**: Effect of candidate blood cancer therapies on normal human lymphocytes (Fruman)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

**Opening soon**
Malignant Hematology Clinical Trials

**CLL**

**UCI 15-88**
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia (O’Brien)

**UCI 17-03**
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects with Treatment Naïve Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (O’Brien)

**UCI 16-95**
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies (O’Brien)

**UCI 15-18**
An Open-Label, Multicenter Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy (O’Brien)

**UCI 16-65**
A Phase 1 clinical trial to evaluate obinutuzumab with high-dose Ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent Ibrutinib (Jeyakumar)

**UCI 17-19 (CLL/SLL/Richters)**
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O’Brien)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.1017

**Opening soon**
**Malignant Hematology Clinical Trials**

**ECOG E1910**
A phase II Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia (ALL) (Jeyakumar)

**UCI 15-58**
*SUSPENDED*
A Phase I/II Study Evaluating KTE-C19 in Subjects with Relapsed/Refractory ALL (O’Brien)

**SWOG S1318 (Ph- Only)**
*SUSPENDED*
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 18 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (Jeyakumar)

**UCI 16-10**
A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL) (O’Brien)

**UCI 16-13**
A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

**UCI 16-95**
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies (O’Brien)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

**V.1017**

**Opening soon**
<table>
<thead>
<tr>
<th>T-Cell</th>
<th>Lymphoma</th>
<th>B-Cell</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UCI 16-45</strong>&lt;br&gt;A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K δ/γ inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma. (Pinter-Brown)</td>
<td><strong>ECOG-EAY131</strong>&lt;br&gt;Molecular Analysis for Therapy Choice (MATCH). (Seery)</td>
<td><strong>UCI 17-58</strong>&lt;br&gt;Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas. (Pinter-Brown)</td>
</tr>
<tr>
<td><strong>UCI 16-46</strong>&lt;br&gt;A Phase 1 dose-ranging study to investigate the safety, tolerability, and pharmacokinetics of MRG-106 following local intratumoral and subcutaneous injection in patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) sub-type. (Pinter-Brown)</td>
<td><strong>UCI 16-13</strong>&lt;br&gt;A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)</td>
<td><strong>UCI 16-95</strong>&lt;br&gt;A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies (O’Brien)</td>
</tr>
<tr>
<td><strong>UCI 17-36</strong>&lt;br&gt;A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma. (Pinter-Brown)</td>
<td><strong>UCI 17-19 (T-Cell/NHL)</strong>&lt;br&gt;A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O’Brien)</td>
<td><strong>UCI 15-18</strong>&lt;br&gt;An Open-Label, Multicenter Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy (O’Brien)</td>
</tr>
</tbody>
</table>

For more details contact 1-877-UC-Study OR ucstudy.uci.edu
AML

**UCI 16-100**
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy (Jeyakumar)

**UCI 15-69**
Phase 3 study of ASP2215 vs. Salvage Chemo in Pts w/ Relapsed or Refractory AML w/ FLT3 Mutation (Jeyakumar)

**UCI 16-13**
A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

**Opening soon**
Malignant Hematology Clinical Trials

**MALIGNANT HEMATOLOGY**

**MPN**
- **UCI 17-31**
  An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis (Fleischman)

**Multiple Myeloma**
- **ECOG E1A11**
  Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (Brem)

**ECOG-EAY131**
  Molecular Analysis for Therapy Choice (MATCH) (Seery)

**MDS**
- **UCI 14-93**
  Phase 1b Study of Ibrutinib and Azacitidine for the treatment of patients with higher risk MDS (Jeyakumar)

- **UCI 16-13**
  A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

- **UCI 17-19 (Myeloma)**
  A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O’Brien)

- **UCI 14-96**
  A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma (Brem)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

**Opening soon**